AlphaCrest Capital Management’s Regenxbio RGNX Stock Holding History

AlphaCrest Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,000	Closed	-$229K	–	1376
2021 Q4	$229K	Buy	+7,000	New	+$238K	0.01%	1311
2021 Q1	–	Sell	-7,500	Closed	-$340K	–	1286
2020 Q4	$340K	Buy	+7,500	New	+$262K	0.03%	860
2020 Q1	–	Sell	-9,700	Closed	-$397K	–	1238
2019 Q4	$397K	Buy	9,700 +1,600	+20%	+$63.2K	0.03%	917
2019 Q3	$288K	Buy	+8,100	New	+$328K	0.02%	1106

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaCrest Capital Management's RGNX Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Regenxbio (RGNX) in Q1 2022, closing a stake of 7,000 shares — an estimated $229K sold.

AlphaCrest Capital Management first reported a position in RGNX in Q3 2019 and held it in 4 quarters. The position peaked at $397K in Q4 2019. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2022.

AlphaCrest Capital Management reported no remaining Regenxbio position as of Q1 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 7,000 Regenxbio shares in Q1 2022, an estimated $229K.
AlphaCrest Capital Management first reported a position in Regenxbio in Q3 2019 and held it in 4 quarters.
AlphaCrest Capital Management's Regenxbio position peaked at $397K in Q4 2019.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.